I don't expect the med-tech sector to match the performance of 2013 this year, but I continue to believe that Novadaq (NASDAQ:NVDQ) will be a market-beater. Novadaq has only just begun to show what its imaging technology can do in terms of clinical results, market share, and revenue. As time goes on, I expect this company to be one of the most impressive growth stories in med-tech, and a stock well worth owning.
PINPOINTing The Opportunity
A lot of Novadaq's future rides on the success of its PINPOINT endoscopic fluorescence imaging system ("Pinpoint"). As the name might suggest, this is an endoscopic system that allows surgeons to visualize anastomoses and perfusion during minimally invasive procedures. Insufficient bloodflow and...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|